Sangamo Therapeutics Enters Research Evaluation and Option Agreement with Prevail Therapeutics

1 Mins read

Sangamo Therapeutics, a leading biotechnology company, announced on Monday a research evaluation and option agreement with Prevail Therapeutics, a subsidiary of Eli Lilly and Company.

Evaluating Proprietary Sangamo Adeno-Associated Virus Capsids

As part of the global agreement, Prevail will receive the rights to conduct in vitro and in vivo studies to evaluate specific proprietary Sangamo adeno-associated virus capsids. In return, Sangamo will receive an upfront payment.

Exclusive License for Multiple Neurological Targets

In addition to the evaluation rights, Prevail also has the option to secure an exclusive license for the use of the capsids across multiple undisclosed neurological targets.

Potential Financial Benefits for Sangamo

Should Prevail choose to exercise the option for all targets and successfully gain approval for a Prevail product utilizing the licensed capsids in both the United States and Europe, Sangamo stands to benefit significantly. This includes:

  • Up to $415 million in exercise fees and developmental milestone payments
  • Up to $775 million in commercial milestone payments
  • Tiered royalties based on net sales of Prevail products

Prevail’s Responsibility for Development and Commercialization

Under the agreement, Prevail will take the lead in all future development, manufacturing, and commercialization efforts related to the products.

Positive Market Reaction

News of the agreement has had a positive impact on Sangamo Therapeutics’ market performance. As of premarket trading on Monday, the company’s shares rose by 12% to $1.44.

Related posts

Banking Regulations for Preventing Failures

2 Mins read
Banking regulators have the power to prevent future bank collapses, according to a panel of banking experts who emphasized the importance of…

Dave's Strong Q4 Performance

1 Mins read
Shares of Dave surged on Tuesday following the digital bank’s announcement of a profitable fourth quarter earlier than expected, with a positive…

DaVita Expands in Latin America

1 Mins read
Shares of DaVita reached record levels as the kidney care services company announced its significant expansion into Latin America through a $300…

Leave a Reply

Your email address will not be published. Required fields are marked *

29 − = 24